1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > Allergies - Pipeline Review, H2 2013

Allergies - Pipeline Review, H2 2013

  • August 2013
  • -
  • Global Markets Direct
  • -
  • 156 pages

Allergies - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Allergies - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Allergies, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergies. Allergies - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Allergies.
- A review of the Allergies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Allergies pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Allergies.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Allergies pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Allergies - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Allergies Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Allergies 10
Allergies Therapeutics under Development by Companies 12
Allergies Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Allergies Therapeutics - Products under Development by Companies 21
Allergies Therapeutics - Products under Investigation by Universities/Institutes 23
Companies Involved in Allergies Therapeutics Development 24
Shionogi and Co., Ltd. 24
AstraZeneca PLC 25
GlaxoSmithKline plc 26
Biotec Pharmacon ASA 27
United Biomedical, Inc. 28
Dainippon Sumitomo Pharma Co., Ltd. 29
BioLineRx, Ltd. 30
Novartis AG 31
Actelion Ltd 32
ALK-Abello A/S 33
Japan Tobacco Inc. 34
IntelGenx Technologies Corp. 35
Idera Pharmaceuticals, Inc. 36
Cytos Biotechnology AG 37
Proteo, Inc. 38
Antigen Express, Inc. 39
ActogeniX NV 40
Immupharma Plc 41
EpiVax, Inc. 42
Indus Biotech Private Limited 43
Monosol Rx, LLC 44
Xencor, Inc. 45
Immune Design Inc. 46
ANERGIS SA 47
SIFI S.p.A 48
SuppreMol GmbH 49
Viromed Co., Ltd. 50
Interprotein Corporation 51
ImmunoFrontier, Inc. 52
Biomay AG 53
NAL Pharmaceuticals Ltd. 54
Vaxine Pty Ltd 55
RaQualia Pharma Inc. 56
ToleroTech Inc. 57
Clarassance, Inc. 58
Allergies - Therapeutics Assessment 59
Assessment by Monotherapy Products 59
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
IMO-2134 - Drug Profile 64
AM-461 - Drug Profile 65
ActoBiotics For Allergic Disease - Drug Profile 66
INDUS-82010 - Drug Profile 67
Leech-Derived Tryptase Inhibitor - Drug Profile 68
S-555739 - Drug Profile 69
S-555739 - Drug Profile 71
S-555739 - Drug Profile 73
AM-211 - Drug Profile 75
SF-107 - Drug Profile 76
IgE Inhibitor - Drug Profile 77
IPZ-010 - Drug Profile 78
AVP-13358 - Drug Profile 79
Soluble Beta Glucan - Drug Profile 80
ZPL-3893787 - Drug Profile 83
IPP-201007 - Drug Profile 84
RQ-00000008 - Drug Profile 85
ALK Next Generation Vaccine - Drug Profile 86
Novel Immunotherapeutics - Drug Profile 87
PG-102 - Drug Profile 88
UBI Anti-IgE Vaccine - Drug Profile 89
XmAb-7195 - Drug Profile 90
Vaccine For Allergy - Drug Profile 91
Fve Polypeptide - Drug Profile 92
QGE-031 - Drug Profile 93
QGE-031 - Drug Profile 95
Cytokine-Like Proteins - Drug Profile 97
JDP-207 - Drug Profile 98
Anti-Allergy siRNA - Drug Profile 99
Tregitopes for Allergy - Drug Profile 100
CRTH-2 Receptor Antagonist - Drug Profile 101
Insect Bite Allergy Vaccine - Drug Profile 102
GSK-2245035 - Drug Profile 103
JTE-051 - Drug Profile 105
AZ-12441970 - Drug Profile 106
SM-324405 - Drug Profile 107
Vaccine for Allergy - Drug Profile 108
BL-9010 - Drug Profile 109
GE-2 - Drug Profile 110
JDP-205 - Drug Profile 112
Allergen Vaccine Program - Drug Profile 113
INT-0023 - Drug Profile 114
grapiprant - Drug Profile 115
brompheniramine - Drug Profile 117
BM-10 - Drug Profile 118
VLP-IgE Vaccine - Drug Profile 119
Therapeutic Antibody B-3 - Drug Profile 120
Therapeutic Protein B-3FP - Drug Profile 121
JTE-052 - Drug Profile 122
Histamine H1/H4 Receptor Antagonist - Drug Profile 123
Spleen Tyrosine Kinase Inhibitor Program - Drug Profile 124
SM-301 - Drug Profile 125
ABX-301 - Drug Profile 126
Drug For Allergy - Drug Profile 127
denileukin diftitox - Drug Profile 128
Tolergentide - Drug Profile 129
MS Program - Drug Profile 130
XGP-515 - Drug Profile 131
Next Generation Histamine H4 Antagonists - Drug Profile 132
AllerB - Drug Profile 133
omalizumab Biosmiliar - Drug Profile 134
FB-301 - Drug Profile 135
MB-11319 - Drug Profile 136
Allergies Therapeutics - Drug Profile Updates 137
Allergies Therapeutics - Discontinued Products 143
Allergies Therapeutics - Dormant Products 144
Allergies - Product Development Milestones 146
Featured News and Press Releases 146
Appendix 151
Methodology 151
Coverage 151
Secondary Research 151
Primary Research 151
Expert Panel Validation 151
Contact Us 152
Disclaimer 152



List of Tables

Number of Products Under Development for Allergies, H2 2013 14
Products under Development for Allergies - Comparative Analysis, H2 2013 15
Number of Products under Development by Companies, H2 2013 17
Number of Products under Development by Companies, H2 2013 (Contd..1) 18
Number of Products under Development by Companies, H2 2013 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2013 20
Comparative Analysis by Late Stage Development, H2 2013 21
Comparative Analysis by Mid Clinical Stage Development, H2 2013 22
Comparative Analysis by Early Clinical Stage Development, H2 2013 23
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 24
Products under Development by Companies, H2 2013 25
Products under Development by Companies, H2 2013 (Contd..2) 26
Products under Investigation by Universities/Institutes, H2 2013 27
Shionogi and Co., Ltd., H2 2013 28
AstraZeneca PLC, H2 2013 29
GlaxoSmithKline plc, H2 2013 30
Biotec Pharmacon ASA, H2 2013 31
United Biomedical, Inc., H2 2013 32
Dainippon Sumitomo Pharma Co., Ltd., H2 2013 33
BioLineRx, Ltd., H2 2013 34
Novartis AG, H2 2013 35
Actelion Ltd, H2 2013 36
ALK-Abello A/S, H2 2013 37
Japan Tobacco Inc., H2 2013 38
IntelGenx Technologies Corp., H2 2013 39
Idera Pharmaceuticals, Inc., H2 2013 40
Cytos Biotechnology AG, H2 2013 41
Proteo, Inc., H2 2013 42
Antigen Express, Inc., H2 2013 43
ActogeniX NV, H2 2013 44
Immupharma Plc, H2 2013 45
EpiVax, Inc., H2 2013 46
Indus Biotech Private Limited, H2 2013 47
Monosol Rx, LLC, H2 2013 48
Xencor, Inc., H2 2013 49
Immune Design Inc., H2 2013 50
ANERGIS SA, H2 2013 51
SIFI S.p.A, H2 2013 52
SuppreMol GmbH, H2 2013 53
Viromed Co., Ltd., H2 2013 54
Interprotein Corporation, H2 2013 55
ImmunoFrontier, Inc., H2 2013 56
Biomay AG, H2 2013 57
NAL Pharmaceuticals Ltd., H2 2013 58
Vaxine Pty Ltd, H2 2013 59
RaQualia Pharma Inc., H2 2013 60
ToleroTech Inc., H2 2013 61
Clarassance, Inc., H2 2013 62
Assessment by Monotherapy Products, H2 2013 63
Assessment by Stage and Route of Administration, H2 2013 65
Assessment by Stage and Molecule Type, H2 2013 67
Allergies Therapeutics - Drug Profile Updates 141
Allergies Therapeutics - Discontinued Products 147
Allergies Therapeutics - Dormant Products 148
Allergies Therapeutics - Dormant Products (Contd..2) 149



List of Figures

Number of Products under Development for Allergies, H2 2013 14
Products under Development for Allergies - Comparative Analysis, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 20
Late Stage Products, H2 2013 21
Mid Clinical Stage Products, H2 2013 22
Early Clinical Stage Products, H2 2013 23
Discovery and Pre-Clinical Stage Products, H2 2013 24
Assessment by Monotherapy Products, H2 2013 63
Assessment by Route of Administration, H2 2013 64
Assessment by Stage and Route of Administration, H2 2013 65
Assessment by Molecule Type, H2 2013 66
Assessment by Stage and Molecule Type, H2 2013 67



Companies Mentioned

Shionogi and Co., Ltd.
AstraZeneca PLC
GlaxoSmithKline plc
Biotec Pharmacon ASA
United Biomedical, Inc.
Dainippon Sumitomo Pharma Co., Ltd.
BioLineRx, Ltd.
Novartis AG
Actelion Ltd
ALK-Abello A/S
Japan Tobacco Inc.
IntelGenx Technologies Corp.
Idera Pharmaceuticals, Inc.
Cytos Biotechnology AG
Proteo, Inc.
Antigen Express, Inc.
ActogeniX NV
Immupharma Plc
EpiVax, Inc.
Indus Biotech Private Limited
Monosol Rx, LLC
Xencor, Inc.
Immune Design Inc.
ANERGIS SA
SIFI S.p.A
SuppreMol GmbH
Viromed Co., Ltd.
Interprotein Corporation
ImmunoFrontier, Inc.
Biomay AG
NAL Pharmaceuticals Ltd.
Vaxine Pty Ltd
RaQualia Pharma Inc.
ToleroTech Inc.
Clarassance, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Cetirizine Dihydrochloride Industry Market Report

2016 Cetirizine Dihydrochloride Industry Market Report

  • $ 2800
  • Industry report
  • August 2016
  • by Prof Research

The 'Global and Chinese Cetirizine Dihydrochloride Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Cetirizine Dihydrochloride industry ...

2016 Global and Chinese Loratadine Industry Market Research Report

2016 Global and Chinese Loratadine Industry Market Research Report

  • $ 2800
  • Industry report
  • September 2016
  • by Prof Research

The 'Global and Chinese Loratadine Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Loratadine industry with a focus on the Chinese market. ...

2016 Global Doxylamine (CAS 469-21-6) Industry Market Report

2016 Global Doxylamine (CAS 469-21-6) Industry Market Report

  • $ 2800
  • Industry report
  • August 2016
  • by Prof Research

The 'Global and Chinese Doxylamine Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Doxylamine industry with a focus on the Chinese market. ...

Consumer Health In The Us

September 2016 $ 2423

Consumer Health In Venezuela

September 2016 $ 2423

Consumer Health In Poland

September 2016 $ 2423

Download Unlimited Documents from Trusted Public Sources

Allergy Drug Consumer Insights in the UK

  • April 2016
    6 pages
  • Allergy Drug  

  • United Kingdom  

    Europe  

View report >

Allergy Drug Markets in Australia and New Zealand

  • January 2016
    38 pages
  • Allergy Drug  

    Therapy  

    Respiratory Dis...  

  • Australia  

    New Zealand  

    Oceania  

View report >

Allergy Drug Industry in the UK

  • January 2016
    7 pages
  • Allergy Drug  

    Food  

  • United Kingdom  

View report >

Otc Markets In India

24 days ago

Related Market Segments :

Allergy Drug

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.